{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:10:00Z","timestamp":1763554200746,"version":"3.45.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the General Project of the Natural Science Foundation of the Chongqing Science and Technology Bureau","award":["CSTB2024NSCQ-MSX0085"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX0085"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11096-025-02027-6","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:13:08Z","timestamp":1761225188000},"page":"2051-2060","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative evaluation of pregnancy-related adverse events associated with proton pump inhibitors using the FDA adverse event reporting system database"],"prefix":"10.1007","volume":"47","author":[{"given":"Wenjuan","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuye","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"5","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/ncpgasthep0452","volume":"3","author":"C Thukral","year":"2006","unstructured":"Thukral C, Wolf JL. Therapy insight: drugs for gastrointestinal disorders in pregnant women. Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):256\u201366. https:\/\/doi.org\/10.1038\/ncpgasthep0452.","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"2","key":"2027_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.gtc.2016.02.005","volume":"45","author":"C Body","year":"2016","unstructured":"Body C, Christie JA. Gastrointestinal diseases in pregnancy: nausea, vomiting, hyperemesis gravidarum, gastroesophageal reflux disease, constipation, and diarrhea. Gastroenterol Clin N Am. 2016;45(2):267\u201383. https:\/\/doi.org\/10.1016\/j.gtc.2016.02.005.","journal-title":"Gastroenterol Clin N Am"},{"issue":"3","key":"2027_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.pop.2023.03.002","volume":"50","author":"J Patel","year":"2023","unstructured":"Patel J, Wong N, Mehta K, et al. Gastroesophageal reflux disease. Primary Care Clin Office Pract. 2023;50(3):339\u201350. https:\/\/doi.org\/10.1016\/j.pop.2023.03.002.","journal-title":"Primary Care Clin Office Pract"},{"issue":"5","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"366","DOI":"10.7326\/0003-4819-118-5-199303010-00008","volume":"118","author":"TH Baron","year":"1993","unstructured":"Baron TH, Ramirez B, Richter JE. Gastrointestinal motility disorders during pregnancy. Ann Intern Med. 1993;118(5):366\u201375. https:\/\/doi.org\/10.7326\/0003-4819-118-5-199303010-00008.","journal-title":"Ann Intern Med"},{"issue":"35","key":"2027_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030487","volume":"101","author":"M Altuwaijri","year":"2022","unstructured":"Altuwaijri M. Evidence-based treatment recommendations for gastroesophageal reflux disease during pregnancy: a review. Medicine (Baltimore). 2022;101(35):e30487. https:\/\/doi.org\/10.1097\/MD.0000000000030487.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2027_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/0002-9378(48)90463-3","volume":"56","author":"JB Bernstine","year":"1948","unstructured":"Bernstine JB, Friedman MHF. Peptic ulcer in pregnancy. Am J Obstet Gynecol. 1948;56(5):973\u20136. https:\/\/doi.org\/10.1016\/0002-9378(48)90463-3.","journal-title":"Am J Obstet Gynecol"},{"key":"2027_CR7","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2147\/IJWH.S467056","volume":"16","author":"X Han","year":"2024","unstructured":"Han X, Wu TQ, Yao R, et al. Gastroesophageal reflux disease and preterm birth: univariate and multivariate Mendelian randomization. Int J Womens Health. 2024;16:1389\u201399. https:\/\/doi.org\/10.2147\/IJWH.S467056.","journal-title":"Int J Womens Health"},{"issue":"1","key":"2027_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0889-8553(05)70351-4","volume":"27","author":"PO Katz","year":"1998","unstructured":"Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin N Am. 1998;27(1):153\u201367. https:\/\/doi.org\/10.1016\/S0889-8553(05)70351-4.","journal-title":"Gastroenterol Clin N Am"},{"issue":"12","key":"2027_CR9","doi-asserted-by":"publisher","first-page":"919","DOI":"10.14423\/SMJ.0000000000001473","volume":"115","author":"MA Barnhart","year":"2022","unstructured":"Barnhart MA, Thomas ML, Schilthuis AJ, et al. Know your guidelines series: the ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease review. South Med J. 2022;115(12):919\u201320. https:\/\/doi.org\/10.14423\/SMJ.0000000000001473.","journal-title":"South Med J"},{"issue":"4","key":"2027_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.rgmx.2016.04.003","volume":"81","author":"F Huerta-Iga","year":"2016","unstructured":"Huerta-Iga F, Bielsa-Fern\u00e1ndez MV, Remes-Troche JM, et al. Diagn\u00f3stico y tratamiento de la enfermedad por reflujo gastroesof\u00e1gico: recomendaciones de la Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Rev Gastroenterol Mex. 2016;81(4):208\u201322. https:\/\/doi.org\/10.1016\/j.rgmx.2016.04.003.","journal-title":"Rev Gastroenterol Mex"},{"issue":"1","key":"2027_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.rgmxen.2023.12.002","volume":"89","author":"MA Valdovinos D\u00edaz","year":"2024","unstructured":"Valdovinos D\u00edaz MA, Amieva-Balmori M, Carmona-S\u00e1nchez R, et al. Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociaci\u00f3n Mexicana de Gastroenterolog\u00eda. Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition). 2024;89(1):121\u201343. https:\/\/doi.org\/10.1016\/j.rgmxen.2023.12.002.","journal-title":"Revista de Gastroenterolog\u00eda de M\u00e9xico (English Edition)"},{"key":"2027_CR12","unstructured":"Schaefer C, Peters PWJ, Miller RK, eds. Drugs during pregnancy and lactation: treatment options and risk assessment. 2nd ed. Elsevier;2007."},{"issue":"8","key":"2027_CR13","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s00247-025-06284-5","volume":"55","author":"H \u00d6nner","year":"2025","unstructured":"\u00d6nner H, Calderon Tobar MN, Sar\u0131kaya M, et al. Premedication in pediatric Meckel scintigraphy: pantoprazole versus ranitidine for optimizing scan quality. Pediatr Radiol. 2025;55(8):1713\u20138. https:\/\/doi.org\/10.1007\/s00247-025-06284-5.","journal-title":"Pediatr Radiol"},{"issue":"5","key":"2027_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12664-023-01428-7","volume":"42","author":"AK Dutta","year":"2023","unstructured":"Dutta AK, Jain A, Jearth V, et al. Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship. Indian J Gastroenterol. 2023;42(5):601\u201328. https:\/\/doi.org\/10.1007\/s12664-023-01428-7.","journal-title":"Indian J Gastroenterol"},{"issue":"4","key":"2027_CR15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/apt.15611","volume":"51","author":"CS Th\u00e9lin","year":"2020","unstructured":"Th\u00e9lin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. Aliment Pharmacol Ther. 2020;51(4):421\u201334. https:\/\/doi.org\/10.1111\/apt.15611.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"2027_CR16","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0889","volume":"141","author":"T Lai","year":"2018","unstructured":"Lai T, Wu M, Liu J, et al. Acid-suppressive drug use during pregnancy and the risk of childhood asthma: a meta-analysis. Pediatrics. 2018;141(2):e20170889. https:\/\/doi.org\/10.1542\/peds.2017-0889.","journal-title":"Pediatrics"},{"issue":"2","key":"2027_CR17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12539-019-00335-w","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Shi D, Abagyan R, et al. Population scale retrospective analysis reveals potential risk of cholestasis in pregnant women taking omeprazole, lansoprazole, and amoxicillin. Interdiscip Sci Comput Life Sci. 2019;11(2):273\u201381. https:\/\/doi.org\/10.1007\/s12539-019-00335-w.","journal-title":"Interdiscip Sci Comput Life Sci"},{"issue":"4","key":"2027_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/apt.15610","volume":"51","author":"CM Li","year":"2020","unstructured":"Li CM, Zhernakova A, Engstrand L, et al. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. Aliment Pharmacol Ther. 2020;51(4):410\u201320. https:\/\/doi.org\/10.1111\/apt.15610.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"2027_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.50366","volume":"6","author":"A Choi","year":"2023","unstructured":"Choi A, Noh Y, Jeong HE, et al. Association between proton pump inhibitor use during early pregnancy and risk of congenital malformations. JAMA Netw Open. 2023;6(1):e2250366. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50366.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"2027_CR20","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1080\/14740338.2024.2359615","volume":"23","author":"W Dou","year":"2024","unstructured":"Dou W, Liu X, An P, et al. Real-world safety profile of tetracyclines in children younger than 8 years old: an analysis of FAERS database and review of case report. Expert Opin Drug Saf. 2024;23(7):885\u201392. https:\/\/doi.org\/10.1080\/14740338.2024.2359615.","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2027_CR21","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1212\/WNL.0000000000207375","volume":"101","author":"MF Brin","year":"2023","unstructured":"Brin MF, Kirby RS, Slavotinek A, et al. Pregnancy outcomes in patients exposed to OnabotulinumtoxinA treatment: a cumulative 29-year safety update. Neurology. 2023;101(2):e103\u201313. https:\/\/doi.org\/10.1212\/WNL.0000000000207375.","journal-title":"Neurology"},{"issue":"1","key":"2027_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s10194-024-01913-0","volume":"25","author":"WH Liu","year":"2024","unstructured":"Liu WH, Hu HM, Li C, et al. Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database. J Headache Pain. 2024;25(1):206. https:\/\/doi.org\/10.1186\/s10194-024-01913-0.","journal-title":"J Headache Pain"},{"issue":"1","key":"2027_CR23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-025-00714-7","volume":"26","author":"M Xu","year":"2025","unstructured":"Xu M, Xu S, Yi X. A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database. BMC Immunol. 2025;26(1):35. https:\/\/doi.org\/10.1186\/s12865-025-00714-7.","journal-title":"BMC Immunol"},{"issue":"1","key":"2027_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B, et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA adverse event reporting system database. BMC Med. 2024;22(1):65. https:\/\/doi.org\/10.1186\/s12916-024-03274-6.","journal-title":"BMC Med"},{"issue":"6","key":"2027_CR25","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/MCG.0000000000000854","volume":"51","author":"R Hunt","year":"2017","unstructured":"Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation global guidelines: GERD global perspective on gastroesophageal reflux disease. J Clin Gastroenterol. 2017;51(6):467\u201378. https:\/\/doi.org\/10.1097\/MCG.0000000000000854.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"2027_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.therap.2020.06.019","volume":"76","author":"A Koyyada","year":"2021","unstructured":"Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. Therapie. 2021;76(1):13\u201321. https:\/\/doi.org\/10.1016\/j.therap.2020.06.019.","journal-title":"Therapie"},{"issue":"3","key":"2027_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10620-011-1940-3","volume":"57","author":"I Matok","year":"2012","unstructured":"Matok I, Levy A, Wiznitzer A, et al. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci. 2012;57(3):699\u2013705. https:\/\/doi.org\/10.1007\/s10620-011-1940-3.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"2027_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00404-007-0319-3","volume":"276","author":"A Mayer","year":"2007","unstructured":"Mayer A, Sheiner E, Holcberg G. Zollinger Ellison syndrome, treated with lansoprazole, during pregnancy. Arch Gynecol Obstet. 2007;276(2):171\u20133. https:\/\/doi.org\/10.1007\/s00404-007-0319-3.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2027_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10266-022-00749-x","volume":"111","author":"M Fr\u00edtola","year":"2023","unstructured":"Fr\u00edtola M, Sestario CS, Martins CCN, et al. Intrauterine exposure to omeprazole increases the risk of teeth morphological anomalies in the offspring of a murine model. Odontology. 2023;111(2):401\u20138. https:\/\/doi.org\/10.1007\/s10266-022-00749-x.","journal-title":"Odontology"},{"key":"2027_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2023.108419","volume":"119","author":"A Peron","year":"2023","unstructured":"Peron A, Ripoche E, Picot C, et al. Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations. Reprod Toxicol. 2023;119:108419. https:\/\/doi.org\/10.1016\/j.reprotox.2023.108419.","journal-title":"Reprod Toxicol"},{"issue":"10","key":"2027_CR31","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamapediatrics.2023.2900","volume":"177","author":"M Lassalle","year":"2023","unstructured":"Lassalle M, Zureik M, Dray-Spira R. Proton pump inhibitor use and risk of serious infections in young children. JAMA Pediatr. 2023;177(10):1028\u201338. https:\/\/doi.org\/10.1001\/jamapediatrics.2023.2900.","journal-title":"JAMA Pediatr"},{"issue":"3","key":"2027_CR32","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40264-024-01496-4","volume":"48","author":"M Tisseyre","year":"2025","unstructured":"Tisseyre M, Collier M, Beeker N, et al. Prenatal exposure to proton pump inhibitors and risk of serious infections in offspring during the first year of life: a nationwide cohort study. Drug Saf. 2025;48(3):265\u201377. https:\/\/doi.org\/10.1007\/s40264-024-01496-4.","journal-title":"Drug Saf"},{"issue":"1","key":"2027_CR33","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12916-022-02673-x","volume":"20","author":"EM Breddels","year":"2022","unstructured":"Breddels EM, Simin J, Fornes R, et al. Population-based cohort study: proton pump inhibitor use during pregnancy in Sweden and the risk of maternal and neonatal adverse events. BMC Med. 2022;20(1):492. https:\/\/doi.org\/10.1186\/s12916-022-02673-x.","journal-title":"BMC Med"},{"issue":"4","key":"2027_CR34","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7962","volume":"6","author":"A Choi","year":"2023","unstructured":"Choi A, Noh Y, Yon DK, et al. Maternal proton pump inhibitor use during pregnancy and risk of low birth weight in offspring in Korea, 2008\u20132019. JAMA Netw Open. 2023;6(4):e237962. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.7962.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"2027_CR35","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/s0024-3205(01)01135-3","volume":"69","author":"K Yildirim","year":"2001","unstructured":"Yildirim K, Sarioglu Y, Kaya T, et al. Inhibitor effect of omeprazole in isolated human myometrial smooth muscle. Life Sci. 2001;69(4):435\u201342. https:\/\/doi.org\/10.1016\/s0024-3205(01)01135-3.","journal-title":"Life Sci"},{"key":"2027_CR36","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2013.10.007","volume":"52","author":"C Terranova","year":"2014","unstructured":"Terranova C, Petrella C, Improta G, et al. Relaxant effect of proton pump inhibitors on in vitro myometrium from pregnant women. Eur J Pharm Sci. 2014;52:125\u201331. https:\/\/doi.org\/10.1016\/j.ejps.2013.10.007.","journal-title":"Eur J Pharm Sci"},{"issue":"3","key":"2027_CR37","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/HYPERTENSIONAHA.117.09741","volume":"70","author":"L Saleh","year":"2017","unstructured":"Saleh L, Samantar R, Garrelds IM, et al. Low soluble Fms-like tyrosine kinase-1, endoglin, and endothelin-1 levels in women with confirmed or suspected preeclampsia using proton pump inhibitors. Hypertension. 2017;70(3):594\u2013600. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.09741.","journal-title":"Hypertension"},{"issue":"5","key":"2027_CR38","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/HYPERTENSIONAHA.118.12547","volume":"73","author":"R Hastie","year":"2019","unstructured":"Hastie R, Bergman L, Cluver CA, et al. Proton pump inhibitors and preeclampsia risk among 157 720 women. Hypertension. 2019;73(5):1097\u2013103. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12547.","journal-title":"Hypertension"},{"issue":"6","key":"2027_CR39","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1161\/HYPERTENSIONAHA.122.19070","volume":"79","author":"RI Neuman","year":"2022","unstructured":"Neuman RI, Baars MD, Saleh L, et al. Omeprazole administration in preterm preeclampsia: a randomized controlled trial to study its effect on sFlt-1 (soluble fms-like tyrosine kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1). Hypertension. 2022;79(6):1297\u2013307. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19070.","journal-title":"Hypertension"},{"issue":"14","key":"2027_CR40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1055\/s-0040-1713864","volume":"38","author":"NA Bello","year":"2021","unstructured":"Bello NA, Huang Y, Syeda SK, et al. Receipt of proton-pump inhibitors during pregnancy and risk for preeclampsia. Am J Perinatol. 2021;38(14):1519\u201325. https:\/\/doi.org\/10.1055\/s-0040-1713864.","journal-title":"Am J Perinatol"},{"issue":"9","key":"2027_CR41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24339","volume":"4","author":"A Choi","year":"2021","unstructured":"Choi A, Noh Y, Park S-H, et al. Exploration of proton pump inhibitors use during pregnancy and preeclampsia. JAMA Netw Open. 2021;4(9):e2124339. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.24339.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2027_CR42","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala HJ, Tonning JM, Smith E, et al. Use of data mining at the Food and Drug Administration. J Am Med Inform Assoc. 2016;23(2):428\u201334. https:\/\/doi.org\/10.1093\/jamia\/ocv063.","journal-title":"J Am Med Inform Assoc"},{"issue":"7","key":"2027_CR43","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"key":"2027_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772768","volume":"12","author":"R Yang","year":"2021","unstructured":"Yang R, Yin N, Zhao Y, et al. Adverse events during pregnancy associated with entecavir and adefovir: new insights from a real-world analysis of cases reported to FDA adverse event reporting system. Front Pharmacol. 2021;12:772768. https:\/\/doi.org\/10.3389\/fphar.2021.772768.","journal-title":"Front Pharmacol"},{"key":"2027_CR45","doi-asserted-by":"publisher","first-page":"1580090","DOI":"10.3389\/fphar.2025.1580090","volume":"16","author":"C Liang","year":"2025","unstructured":"Liang C, Zhang Y. Proton pump inhibitors use and risk of type 2 diabetes mellitus: correlation analysis, prediction model construction, and key genes identification. Front Pharmacol. 2025;16:1580090. https:\/\/doi.org\/10.3389\/fphar.2025.1580090.","journal-title":"Front Pharmacol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-02027-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-02027-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:07:56Z","timestamp":1763554076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-02027-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-02027-6","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"21 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was based on the publicly available FAERS data. Because FAERS contains anonymized reports without identifiable personal information, ethical approval and informed consent were not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}